Hims & Hers Health expands testosterone care with injectable and oral TRT
HIMS•Hims & Hers Health launched three new testosterone treatment options, including twice-weekly subcutaneous and weekly intramuscular injections and FDA-approved oral Kyzatrex. The company said its testosterone offering was scaling rapidly as of the second quarter of 2026.
1. New treatment options
Hims & Hers Health launched three testosterone treatment options: a twice-weekly subcutaneous injection, generic testosterone cypionate for weekly intramuscular injection, and FDA-approved oral Kyzatrex. The company said Kyzatrex is for achieving normal testosterone in 90 days.
2. Offering growth
The company said its testosterone offering was scaling rapidly as of the second quarter of 2026.
